Demand.for.Health.Insurance.and.Services

The Saudi Arabia  Pharmaceuticals and Healthcare Report Q2 –  2017 on this link

https://search-proquest-com.sdl.idm.oclc.org/docview/1882507174?accountid=142908

one of the biggest weaknesses  in the system is the reported lack  of qualified professionals to meet current  and future demand. 

1- summarize the plans initiated by the Saudi Ministry of Health  (MOH) to meet current and future demand. 

2- include whether the MOH should recruit professionals from  other  countries or if they plan to educate internally.  

• Avoid plagiarism 
• in-text citation
• 2 pages
• 4 references
• APA style

For more information, please contact us at: enquiry@bmiresearch.com

+44 (0)20 7246 5170

Saudi Arabia
Pharmaceuticals &
Healthcare Report

Executive Summary

You have downloaded a PDF of BMI’s latest views on the market, summarising the key findings that are
assessed in detail in the new report, as well as the full report Table of Contents.

Find out more about this report by contacting one of our experts on +44 (0)20 7246 5170

For more information, please contact us at: enquiry@bmiresearch.com
+44 (0)20 7246 5170

Saudi Arabia Pharmaceuticals & Healthcare Report Published Date: 01 Jan 2018

Table of contents
BMI Industry View 7

Table: Headline Pharmaceuticals & Healthcare Forecasts (Saudi Arabia 2014-2020) 7
SWOT 9

Industry Forecast 12

Pharmaceutical Market Forecast 12

Table: Pharmaceutical Sales, Historical Data And Forecasts (Saudi Arabia 2012-2020) 15
Healthcare Market Forecast 16

Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 19
Prescription Drug Market Forecast 19

Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 20
Patented Drug Market Forecast 21

Table: Patented Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 22
Generic Drug Market Forecast 23

Table: Generic Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 24
OTC Drug Market Forecast 25

Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 26
Pharmaceutical Trade Forecast 27

Table: Pharmaceutical Trade Data And Forecasts (Saudi Arabia 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Saudi Arabia 2014-2020) 29
Industry Risk/Reward Index 30

Middle East And Africa Risk/Reward Index – Q1 2017 30

Saudi Arabia Risk/Reward Index 38

Rewards 38

Risks 39

Regulatory Review 40

Intellectual Property Issues 41

Pricing Regime 42

Reimbursement Regime 44

Market Overview 45

Healthcare Sector 46

Table: National Transformation Plan – Key Pharmaceutical And Healthcare Objectives For 2020 48
Table: Healthcare Resources (Saudi Arabia 2010-2015) 50
Table: Healthcare Personnel (Saudi Arabia 2010-2015) 51
Table: Healthcare Activity (Saudi Arabia 2010-2015) 51
Research & Development 51

Clinical Trials 53

Epidemiology 54

Competitive Landscape 58

Research-Based Industry 58

Table: Multinational Market Activity 60
Generic Drugmakers 62

Pharmaceutical Distribution 63

For more information, please contact us at: enquiry@bmiresearch.com
+44 (0)20 7246 5170

Pharmaceutical Retail Sector 63

Company Profile 64

GlaxoSmithKline 64

Sanofi 67

SPIMACO 70

TABUK Pharmaceutical Manufacturing 73

Demographic Forecast 76

Demographic Outlook 76

Table: Population Headline Indicators (Saudi Arabia 1990-2025) 77
Table: Key Population Ratios (Saudi Arabia 1990-2025) 77
Table: Urban/Rural Population & Life Expectancy (Saudi Arabia 1990-2025) 78
Table: Population By Age Group (Saudi Arabia 1990-2025) 78
Table: Population By Age Group % (Saudi Arabia 1990-2025) 79
Glossary 81

Methodology 83

Pharmaceutical Expenditure Forecast Model 83

Healthcare Expenditure Forecast Model 83

Notes On Methodology 84

Risk/Reward Index Methodology 85

Index Overview 86

Table: Pharmaceutical Risk/Reward Index Indicators 86
Indicator Weightings 87

For more information, please contact us at: enquiry@bmiresearch.com
+44 (0)20 7246 5170
Saudi Arabia Pharmaceuticals & Healthcare Report Published Date: 01 Jan 2018

BMI View: The pharmaceutical and healthcare markets of Saudi Arabia will be shaped by numerous factors over the
coming years. The gradual rebound in oil prices, a rising chronic disease burden and developments in the healthcare
system will support market expansion and robust opportunities for multinational drugmakers. The emphasis on
cost-containment, protectionist policies towards the local pharmaceutical industry, and lagging regulatory procedures
will remain challenges for innovative drugmakers, yet the size of the market and the overall trend towards raising
medicine access will continue to prove major draws.

Headline Expenditure Projections

Pharmaceuticals: SAR27.9bn (USD7.44bn) in 2016 to SAR28.2bn (USD7.52bn) in 2017; +1.0% in local●

currency and US dollar terms. Forecast in line with Q 4 17 .
Healthcare: SAR129.1bn (USD34.4bn) in 2016 to SAR133.4bn (USD35.6bn) in 2017; +3.3% in local currency●

terms +3.4% in US dollar terms. Forecast in line with Q 4 17 .

Headline Pharmaceuticals & Healthcare Forecasts (Saudi Arabia 2015-2021)

2015 2016 2017f 2018f 2019f 2020f 2021f

Pharmaceutical sales, USDbn 7.520 7.443 7.520 7.898 8.312 8.767 9.269

Pharmaceutical sales, % of GDP 1.15 1.16 1.10 1.08 1.06 1.04 1.04

Pharmaceutical sales, % of health expenditure 21.6 21.6 21.1 21.2 21.3 21.4 21.5

Health spending, USDbn
34.750 34.414 35.573 37.197 38.992 40.966 43.210

f = BMI forecast. Source: National sources, Local news source, Domestic companies, UN Comtrade, BMI

Risk/Reward Index

Saudi Arabia’s status as the largest pharmaceutical market in the Middle East and North Africa bodes well for
its attractiveness to innovative drugmakers, reflected in the kingdom scoring 58.5 out of 100 in BMI’s
Innovative Pharmaceuticals Risk/Reward Index. However, issues relating to patent approvals and the
regulatory system remain a major issue for foreign research-based pharmaceutical players.

Latest Updates

In October 2017, the Saudi Food and Drug Authority (SFDA) announced they will host a three-day●

conference in November 2017 to discuss pharmaceutical legislation, localisation of the medicine industry, as
well as the disease landscape in the kingdom.
In September 2017, the Saudi Health Council approved the establishment of a national committee under its●

supervision to study the issue of high price of some medicines for Hepatitis C, blood diseases and cancer.
In September 2017, Saudi Arabia’s Anfas Medical Care (AMC) and GE Healthcare signed a SAR113mn●

agreement supporting AMC’s new 120-bed specialty facility, catering to chronic disease treatments and due
for opening in Riyadh in 2018.

For more information, please contact us at: enquiry@bmiresearch.com
+44 (0)20 7246 5170

BMI Economic View

Saudi Arabia’s economy will experience a gradual recovery over the coming years, as oil production returns to
positive growth and the government relaxes its austerity drive. While ambitious diversification plans are a
long-term positive for the Saudi economy, we caution that efforts will likely fall short of the stated objectives
and will take time to materialise, offering little benefit to economic growth in the near term. As such, we
forecast real GDP growth to come in at 1.3% in 2018 and 2.0% in 2019, emerging from a projected 0.5%
contraction in 2017.

BMI Political View

Political risk in Saudi Arabia will increase substantially over the next ten years, but the al-Saud family will
retain control of the state’s apparatus. The country will embark on far-reaching economic and social reforms,
which will transform Saudi Arabian society, and erode the welfare state. The risk of seeing conservative forces
push back will increase as reforms progress, while tensions with Iran will persist and impact Saudi Arabia’s
Shi’a minority.

For more information, please contact us at: enquiry@bmiresearch.com
+44 (0)20 7246 5170
Saudi Arabia Pharmaceuticals & Healthcare Report Published Date: 01 Jan 2018

Thank you for downloading BMI’s latest views, we hope you found the information insightful.

To find out more about how the extensive views, analysis and forecasts contained in the full report will
help your company or to discuss your specific information needs please contact one of our experts on
+44 (0)20 7246 5170